SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    A M Gonzalez-Angulo, N Parinyanitikul, X Lei, E A Mittendorf, H Zhang, V Valero, K K Hunt, G N Hortobagyi, M Chavez-MacGregor, Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy, British Journal of Cancer, 2015,

    CrossRef

  2. 2
    Amelia B. Zelnak, Petros Nikolinakos, Jayanthi Srinivasiah, William Jonas, Andrew Pippas, Yuan Liu, Xiaoxian Li, Mylin Torres, Ruth M. O'Regan, High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy, Clinical Breast Cancer, 2015, 15, 1, 31

    CrossRef

  3. 3
    Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber, Dirk M Zahm, Sherko Kümmel, Holger Eidtmann, Peter Klare, Jens Huober, Serban Costa, Hans Tesch, Claus Hanusch, Jörn Hilfrich, Fariba Khandan, Peter A Fasching, Bruno V Sinn, Knut Engels, Keyur Mehta, Valentina Nekljudova, Michael Untch, Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial, The Lancet Oncology, 2014, 15, 7, 747

    CrossRef

  4. 4
    Clara Natoli, Patrizia Vici, Isabella Sperduti, Antonino Grassadonia, Giancarlo Bisagni, Nicola Tinari, Andrea Michelotti, Germano Zampa, Stefania Gori, Luca Moscetti, Michele De Tursi, Michele Panebianco, Maria Mauri, Ilaria Ferrarini, Laura Pizzuti, Corrado Ficorella, Riccardo Samaritani, Lucia Mentuccia, Stefano Iacobelli, Teresa Gamucci, Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer, Journal of Cancer Research and Clinical Oncology, 2013, 139, 7, 1229

    CrossRef

  5. 5
    Susan Dent, Basak Oyan, Arnd Honig, Max Mano, Sacha Howell, HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials, Cancer Treatment Reviews, 2013, 39, 6, 622

    CrossRef

  6. 6
    R. Salmon, L. Ceugnart, J. Selz, C. Hennequin, F. Ettore, A. Gonçalves, Les traitements néoadjuvants TNA (RPC 2013), Oncologie, 2013, 15, 12, 607

    CrossRef

  7. 7
    D. Rea, A. Tomlins, A. Francis, Time to stop operating on breast cancer patients with pathological complete response?, European Journal of Surgical Oncology (EJSO), 2013, 39, 9, 924

    CrossRef

  8. 8
    Sonia Pernas, Miguel Gil-Gil, María Ochoa de Olza, Anna Gumà, Fina Climent, Anna Petit, María Jesús Pla, Amparo García-Tejedor, Ana López-Ojeda, Cati Falo, Adela Fernandez-Otega, Carlos Mesia, Francisco Javier Pérez-Martin, Ander Urruticoechea, Josep Ramon Germà, Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice, Breast Cancer Research and Treatment, 2012, 134, 3, 1161

    CrossRef